Exploring how investors can find highly ranked--Zacks Rank #1 (Strong Buy) or #2 (Buy)--value stocks to buy in July.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Aveanna Healthcare (AVAH) and Align Technology (ALGN) have performed compared to their sector so far this year.
Does Aveanna Healthcare (AVAH) have what it takes to be a top stock pick for momentum investors? Let's find out.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Aveanna (AVAH) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Aveanna Healthcare (AVAH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Aveanna (AVAH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Aveanna Healthcare (AVAH) and Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?
Bullish investors who want to start buying into market weakness might consider adding highly-ranked cheap stocks trading under $10 per share.
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
Aveanna Healthcare NASDAQ: AVAH executives outlined the company's growth strategy, updated 2026 guidance and discussed its newly closed Family First Homecare acquisition during a presentation at William Blair's Growth Stock Conference.
The consensus price target hints at a 50.7% upside potential for Aveanna (AVAH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.